Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Bright Minds Biosciences Inc (BMBIF)

Bright Minds Biosciences Inc (BMBIF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BMBIF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.3410 +25.85%
on 10/22/21
8.9200 -10.54%
on 11/03/21
+0.8000 (+11.14%)
since 10/05/21
3-Month
4.7700 +67.30%
on 08/09/21
8.9200 -10.54%
on 11/03/21
+3.1100 (+63.86%)
since 08/05/21

Most Recent Stories

More News
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

/PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics...

PSIL : 2.90 (-9.09%)
AWKNF : 0.3800 (+8.82%)
ENVB : 4.13 (-13.78%)
MCURF : 0.0580 (+17.65%)
NVMDF : 0.2700 (+35.00%)
BETRF : 0.1374 (-5.89%)
HUGE : 0.8986 (-0.16%)
MSSTF : 0.3755 (-1.55%)
PSYBF : 0.0929 (+4.74%)
PSYCF : 0.0800 (-5.66%)
BMBIF : 7.9800 (-1.85%)
NMDBF : 0.0430 (+1.18%)
KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

/PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics...

AWKNF : 0.3800 (+8.82%)
ENVB : 4.13 (-13.78%)
MCURF : 0.0580 (+17.65%)
NVMDF : 0.2700 (+35.00%)
BETRF : 0.1374 (-5.89%)
MSSTF : 0.3755 (-1.55%)
PSYBF : 0.0929 (+4.74%)
PSYCF : 0.0800 (-5.66%)
BMBIF : 7.9800 (-1.85%)
NMDBF : 0.0430 (+1.18%)
TRYPF : 0.1130 (+11.88%)
WSNAF : 0.0836 (-12.92%)
Bright Minds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC Clearance

VANCOUVER, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused...

DRUG.CN : 1.450 (-0.68%)
BMBIF : 7.9800 (-1.85%)
Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity

-- BMB proprietary 5-HT 2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency --

DRUG.CN : 1.450 (-0.68%)
BMBIF : 7.9800 (-1.85%)
Bright Minds Biosciences Announces Application to List on Nasdaq

VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused...

DRUG.CN : 1.450 (-0.68%)
BMBIF : 7.9800 (-1.85%)
Bright Minds Biosciences Appoints New Board Member and Expands Leadership Team

Additions of industry veterans, Dr. Emer Leahy to the Board of Directors and Dr. Tom Lategan as Vice President of Regulatory Affairs, position the Company to advance drug development programs

DRUG.CN : 1.450 (-0.68%)
BMBIF : 7.9800 (-1.85%)
Bright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond

VANCOUVER, British Columbia, June 11, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused...

DRUG.CN : 1.450 (-0.68%)
BMBIF : 7.9800 (-1.85%)
Bright Minds Biosciences to Present at the 2021 LD Micro Invitational XI

VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused...

DRUG.CN : 1.450 (-0.68%)
BMBIF : 7.9800 (-1.85%)
Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021

VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on...

DRUG.CN : 1.450 (-0.68%)
BMBIF : 7.9800 (-1.85%)

Key Turning Points

3rd Resistance Point 9.1867
2nd Resistance Point 8.8533
1st Resistance Point 8.4167
Last Price 7.9800
1st Support Level 7.6467
2nd Support Level 7.3133
3rd Support Level 6.8767

See More

52-Week High 8.9200
Last Price 7.9800
Fibonacci 61.8% 7.0011
Fibonacci 50% 6.4084
Fibonacci 38.2% 5.8157
52-Week Low 3.8968

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar